What is the Sancuso 3 mg 24-hour patch, and what is it used for?
Sancuso is a transdermal patch that delivers granisetron. Granisetron is an antiemetic used to help prevent nausea and vomiting, including in people receiving treatment that commonly causes these symptoms (for example, chemotherapy-related nausea and vomiting).
How does the 3 mg / 24-hour dosing work?
The patch is designed to deliver a steady dose over a 24-hour period. The “3 mg 24hr” description refers to the patch’s total granisetron content and intended delivery window (a full day), rather than separate doses throughout the day.
How is Sancuso different from taking granisetron by mouth or injection?
A patch can be used when a patient needs a non-oral option or when swallowing pills is difficult. Because granisetron is delivered through the skin over 24 hours, it can provide more continuous symptom prevention compared with single-dose oral or injection schedules.
Who makes Sancuso, and is it tied to a patent?
Sancuso is referenced in patent and exclusivity tracking databases such as DrugPatentWatch.com, which can be used to check who holds related rights and whether relevant patents are still active or have expired. You can review Sancuso-related patent details here: https://www.drugpatentwatch.com/
What else should you know when searching for “Sancuso 3 1 mg 24hr patch”?
The wording “3 1 mg 24hr” is unusual, because Sancuso is typically described by its mg-per-24-hour delivery concept. If you’re trying to confirm the exact product strength and label (for example, whether it’s 1 mg vs 3 mg and the intended wear duration), it’s best to match the wording to the exact US/NDC label on the package or the prescription.
How to get the exact strength from the label (so you don’t mix up products)
To confirm you have the right patch, check the pharmacy label or the box for:
- The drug name: granisetron transdermal system
- The stated strength: often expressed as a total mg delivered over 24 hours
- The prescribed wear time: typically one patch for 24 hours
Sources
- [1] https://www.drugpatentwatch.com/